Clinical Trials on HER2+ Early or Locally Advanced Breast Cancer in Brazil
Total 63 results
-
Instituto do Cancer do Estado de São PauloFundação Faculdade de MedicinaTerminatedLocally Advanced HER2-negative Breast CancerBrazil
-
Instituto do Cancer do Estado de São PauloFundação Faculdade de MedicinaTerminatedLocally Advanced HER2-positive Breast CancerBrazil
-
Hoffmann-La RocheActive, not recruitingEstrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast CancerUnited States, Korea, Republic of, China, Poland, Taiwan, Turkey, United Kingdom, Australia, Argentina, Germany, Singapore, Thailand, Israel, Russian Federation, Ukraine, Brazil, South Africa
-
Hoffmann-La RocheActive, not recruitingEstrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerUnited States, Italy, Korea, Republic of, Canada, Germany, United Kingdom, Australia, Belgium, Brazil, China, Denmark, France, Hong Kong, Portugal, Spain, Taiwan, Turkey, Japan, Argentina, Mexico, Israel, Poland, Russian Federation, A... and more
-
Hoffmann-La RocheActive, not recruitingInflammatory Breast Cancer | Early Breast Cancer | Locally Advanced Breast CancerCanada, Croatia, Spain, Argentina, Mexico, Korea, Republic of, Bosnia and Herzegovina, Brazil, Costa Rica, Turkey, Singapore, Bulgaria, South Africa, India, Peru, Kenya, Chile
-
Novartis PharmaceuticalsCompletedLocally Advanced Breast CancerBrazil
-
AstraZenecaRecruitingLocally Advanced (Inoperable) or Metastatic Breast CancerSpain, Denmark, United States, Korea, Republic of, Germany, Belgium, Vietnam, United Kingdom, France, Japan, Canada, China, India, Malaysia, Taiwan, Thailand, Australia, Turkey, Argentina, Brazil, Poland, Sweden, Italy
-
Hoffmann-La RocheRecruitingLocally Advanced or Metastatic Breast CancerFrance, Belgium, United States, Korea, Republic of, Taiwan, Brazil, China, Italy, Argentina, Jordan, Mexico, Germany, Portugal, Spain, Thailand, United Kingdom, Kenya, Turkey, Hungary, Colombia, India, Oman, Saudi Arabia, Poland, Uganda, United... and more
-
AstraZenecaDaiichi SankyoActive, not recruitingBreast Cancer | Breast Neoplasms | HER2-positive Early Breast CancerUnited States, Italy, Spain, Poland, Taiwan, Thailand, Canada, Germany, Korea, Republic of, Brazil, India, Japan, Peru, Philippines, China, Saudi Arabia, Russian Federation, Bulgaria
-
Hoffmann-La RocheCompletedHER2-Positive Early Breast CancerUnited States, Finland, Hong Kong, Panama, Portugal, Spain, Mexico, Sweden, Brazil, Serbia, Argentina, Lebanon, Cuba, Qatar, Saudi Arabia, Chile, Jordan
-
Gilead SciencesRecruitingStage IV Breast Cancer | Locally Advanced or Unresectable Metastatic Breast CancerTaiwan, Korea, Republic of, Australia, Greece, Spain, United States, United Kingdom, France, Israel, Malaysia, Japan, Belgium, Poland, China, Germany, Czechia, Singapore, Hungary, Brazil, Italy, South Africa, Portugal, Argentina, Hong... and more
-
Latin American Cooperative Oncology GroupRoche Pharma AG; OncoclínicasNot yet recruitingBreast Cancer | HER2-positive Breast CancerBrazil
-
AstraZenecaCompletedMetastatic Breast Cancer | Locally Advanced Breast CancerSweden, United States, Russian Federation, South Africa, United Kingdom, Germany, Hungary, Canada, Belgium, Denmark, Israel, Argentina, France, Brazil, Spain
-
Hoffmann-La RocheRecruitingEstrogen Receptor-Positive, HER2-Negative Advanced Breast CancerBelgium, Korea, Republic of, United States, Canada, China, Italy, France, Brazil, Australia, Argentina, Hong Kong, Portugal, Spain, Taiwan, India, Costa Rica, Israel, Thailand, Germany, New Zealand, Poland, Chile, Colombia, Guatemala, H...
-
Astellas Pharma Global Development, Inc.Active, not recruitingLocally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) AdenocarcinomaUnited States, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Mexico, Peru, Poland, Spain, Taiwan, United Kingdom
-
Instituto do Cancer do Estado de São PauloWithdrawnBreast Cancer | HER-2 Positive Breast CancerBrazil
-
AC Camargo Cancer CenterRecruitingBreast Neoplasms | HER2-positive Breast Cancer | Circulating Tumor CellBrazil
-
Novartis PharmaceuticalsNovartisWithdrawnTreatment for Metastatic or Locally Advanced Cervical CancerBrazil
-
BayerRecruitingLocally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene FusionUnited States, Austria, Denmark, Germany, Italy, Norway, Spain, United Kingdom, Brazil, Russian Federation, Switzerland, Taiwan, Canada, China, Australia, Greece, Belgium, Sweden, Korea, Republic of, France, Argentina, Finland, Ireland and more
-
Novartis PharmaceuticalsCompletedLocally Advanced Cervical CancerBrazil
-
Instituto Nacional de Cancer, BrazilTerminatedChemoradiation | Rectal Cancer, Adenocarcinoma | Locally Advanced Malignant NeoplasmBrazil
-
Hoffmann-La RocheCompletedEarly Breast CancerSpain, Korea, Republic of, Australia, Taiwan, Ukraine, Poland, Russian Federation, United States, Germany, Brazil, Hungary
-
AstraZenecaDaiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, TokyoActive, not recruitingAdvanced or Metastatic Breast CancerUnited States, Belgium, Canada, Denmark, France, Italy, Spain, Hungary, Poland, Taiwan, Russian Federation, Germany, Korea, Republic of, Brazil, Japan, Mexico, United Kingdom, China, Israel, Austria, Australia, Saudi Arabia, Netherl... and more
-
Hoffmann-La RocheCompletedEarly Breast CancerFrance, Spain, United States, Korea, Republic of, Canada, United Kingdom, Argentina, Belgium, Germany, Italy, Taiwan, Thailand, Japan, Brazil, Mexico, Czechia, Poland, Russian Federation, Ukraine
-
PfizerRecruitingAdvanced or Metastatic Breast CancerUnited States, Taiwan, Japan, China, Canada, Korea, Republic of, Israel, Argentina, Australia, Brazil, Mexico, United Kingdom
-
AstraZenecaRecruitingBreast Cancer, Early Breast CancerUnited States, Canada, United Kingdom, China, Argentina, Australia, Hungary, Netherlands, Korea, Republic of, France, Germany, Italy, Belgium, Bulgaria, India, Mexico, Spain, Vietnam, Colombia, Japan, Peru, Brazil, Malaysia, Taiwan, Tha... and more
-
Novartis PharmaceuticalsTranslational Research in OncologyActive, not recruitingEarly Breast CancerUnited States, Belgium, Canada, Italy, United Kingdom, Hungary, Taiwan, Australia, Germany, Spain, Austria, Russian Federation, Korea, Republic of, China, France, Brazil, Ireland, Argentina, Romania, Poland
-
Hoffmann-La RocheRecruitingEarly Breast CancerUnited States, France, Korea, Republic of, Spain, China, Italy, Taiwan, Sweden, Czechia, Hungary, Japan, Greece, Ukraine, Australia, Brazil, Canada, Mexico, Belgium, Argentina, Chile, Serbia, Colombia, Ireland, Hong Kong, Austria, South Africa and more
-
Puma Biotechnology, Inc.CompletedHER2+ Metastatic Breast Cancer (MBC)United States, Canada, Spain, Singapore, Korea, Republic of, Taiwan, United Kingdom, Israel, Australia, Japan, Hong Kong, Finland, Ireland, Italy, France, Portugal, Germany, Sweden, Belgium, Brazil, Czechia, Switzerland, Argentina, Au... and more
-
AstraZenecaAustrian Breast and Colorectal Cancer Study Group (ABCSG)RecruitingBreast Cancer, Early Breast CancerUnited States, Spain, Italy, Korea, Republic of, Belgium, Canada, Poland, Portugal, United Kingdom, France, China, Germany, Japan, Mexico, Thailand, Hungary, Australia, Austria, Brazil, Colombia, Taiwan, Malaysia, Philippines, Romania, ... and more
-
PfizerCompletedAdvanced Breast Cancer FemaleMexico, Argentina, Brazil, Colombia
-
AstraZenecaCompletedAdvanced Breast CancerUnited States, Australia, Brazil
-
Seagen Inc.Merck Sharp & Dohme LLCRecruitingHER2 Positive Breast CancerUnited States, Taiwan, Canada, Korea, Republic of, Austria, China, Spain, Japan, France, Italy, Switzerland, Australia, Belgium, Brazil, Germany, Portugal, United Kingdom, Netherlands, Czechia, Greece, Chile, Finland, Poland
-
AstraZenecaDaiichi SankyoActive, not recruitingBreast Cancer; HER2-positive; MetastaticUnited States, Belgium, Canada, Denmark, Italy, Spain, Hungary, Taiwan, Turkey, France, Germany, Korea, Republic of, Brazil, India, Japan, Peru, Philippines, United Kingdom, China, South Africa, Israel, Russian Federation, Argentina, ... and more
-
Daiichi Sankyo, Inc.AstraZeneca; NSABP Foundation Inc; German Breast Group; Spanish Breast Cancer Research...Active, not recruitingHER2-Positive Primary Breast Cancer | Residual Invasive Breast CancerUnited States, Spain, France, Germany, Korea, Republic of, United Kingdom, Denmark, Israel, Belgium, Taiwan, Chile, Italy, Japan, Peru, Portugal, China, Turkey, Canada, Ireland, Australia, Greece, Czechia, Singapore, Poland, Romania, Arge... and more
-
AstraZenecaActive, not recruitingMetastatic Urothelial Cancer | Unresectable Locally Advanced Urothelial CancerUnited States, Italy, Spain, Canada, Hungary, Poland, Argentina, Thailand, Vietnam, Turkey, Korea, Republic of, Brazil, Czechia, India, Japan, Philippines, Russian Federation, China, Taiwan, Israel, Australia, Bulgaria
-
Instituto do Cancer do Estado de São PauloCompletedPancreatic Adenocarcinoma Advanced or MetastaticBrazil
-
Spexis AGTerminatedMetastatic Breast Cancer | Locally Recurrent Breast CancerSpain, Belgium, United States, United Kingdom, Korea, Republic of, Taiwan, Italy, Russian Federation, Czechia, France, Brazil, Argentina, Ukraine
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
Instituto do Cancer do Estado de São PauloCompletedPhenotype and Prognosis of Patients With Breast Cancer and Pathogenic Variants of TP53 (BREAST-TP53)Breast Cancer | Li-Fraumeni Syndrome | TP53 R337H | Prognosis Breast CancerBrazil
-
Barretos Cancer HospitalCompletedBRCA1 Hereditary Breast and Ovarian Cancer SyndromeBrazil
-
AmgenNo longer availableNon Small-cell Lung Cancer | Locally Advanced Unresectable NSCLC | Locally Advanced Metastatic NSCLCUnited States, Taiwan, Israel, Saudi Arabia, Brazil, Argentina
-
Synta Pharmaceuticals Corp.CompletedBreast Cancer | Triple Negative Breast Cancer | HER-2 Positive Breast Cancer | ER/Progressive Response (PR) + Refractory to Prior Hormonal TreatmentSpain, United States, Argentina, Belgium, Brazil, Korea, Republic of, Peru, United Kingdom
-
Eli Lilly and CompanyCompletedHER-2 Positive Breast Cancer | Hormone Receptor Positive Breast CancerSpain, United States, Korea, Republic of, Belgium, France, Germany, Italy, Australia, Argentina, Canada, United Kingdom, Mexico, Brazil, Greece
-
Novartis PharmaceuticalsCompletedAdvanced, Metastatic Breast CancerUnited States, Canada, France, Italy, Spain, Taiwan, Hungary, Turkey, Belgium, Germany, Netherlands, Singapore, Austria, Czechia, Australia, Israel, Russian Federation, Sweden, United Kingdom, Korea, Republic of, Thailand, Lebanon, ... and more
-
Novartis PharmaceuticalsCompletedAdvanced Metastatic Breast CancerCanada, Italy, Hungary, Taiwan, Turkey, Belgium, Germany, Spain, United States, Singapore, Australia, Korea, Republic of, Hong Kong, Thailand, Lebanon, Bulgaria, France, Russian Federation, Argentina, Brazil, Malaysia, Portugal, Col... and more
-
PfizerArvinas Estrogen Receptor, Inc.RecruitingAdvanced Breast CancerChina, Japan, United States, Taiwan, Canada, Korea, Republic of, Spain, Bulgaria, Turkey, Finland, Italy, Czechia, India, Slovakia, South Africa, Germany, Australia, Brazil, Greece, Puerto Rico, Belgium, Argentina, Switzerland, Poland, ... and more
-
AstraZenecaCompletedLocally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IVUnited States, Poland, France, Germany, Brazil, Hungary, Netherlands, Bulgaria
-
AstraZenecaDaiichi SankyoRecruitingLocally Advanced or Metastatic Non-Small Cell Lung CancerChina, Korea, Republic of, Germany, Italy, Poland, Belgium, Mexico, Turkey, Spain, France, United States, Canada, Taiwan, Brazil, Austria, Hong Kong, India, Japan, Netherlands, Denmark
-
Novartis PharmaceuticalsActive, not recruitingLocally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutationSpain, Italy, Austria, Netherlands, United Kingdom, Germany, Thailand, France, Belgium, China, Argentina, Greece, Turkey, Malaysia, Portugal, Hungary, Brazil, United States, India